Comment
Author: Admin | 2025-04-28
Therapy modificationDimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapyDoxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Monitor therapyDronabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyDroperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Consider therapy modificationEsketamine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyFlunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Consider therapy modificationHYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modificationHydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyKava Kava: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapyLemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Consider therapy modificationLofexidine: May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapyMagnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyMelatonin: May enhance the sedative effect of Hypnotics (Nonbenzodiazepine). Monitor therapyMethotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Consider therapy modificationMetyroSINE: CNS Depressants may enhance the
Add Comment